Please assess the completion status of the following clinical trial:

Trial Title: Memantine and Antipsychotics Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Current diagnosis of probable Alzheimer's disease consistent with NINCDS-ADRDA criteria or with DSM IV TR criteria for Dementia of the Alzheimer's type.~* MRI or CT scan supporting the diagnosis of DAT without indications of any relevant other CNS disorders.~* Patients treated with any acetylcholinesterase inhibitor (AChEI) man be included.~* The patient should have German as a mother-tongue or at least speak the language fluently.~Exclusion criteria:~* Evidence (including CT/MRI results) of any clinically significant central nervous system disease other than Alzheimer's disease.~* Modified Hachinski Ischemia score greater than 4 at screening.~* Intake of any medication that is contra-indicated in combination with memantine.~* Treatment with depot antipsychotics.~* History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to memantine, amantadine or lactose.~* Known or suspected history of alcoholism or drug abuse within the past 10 years.~* Previous treatment with memantine or participation in an investigational study with memantine.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Memantine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).